We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




International Genomics Consortium Licenses Sapphire Biobanking Solution

By Labmedica staff writers
Posted on 21 Jul 2008
The International Genomics Consortium (IGC; Phoenix, AZ, USA) has licenced LabVantage Solutions, Inc (Bridgewater, NJ, USA) Sapphire BioBanking Solution. More...
The IGC chose Sapphire because of its product maturity, functionality, architecture, scalability, and flexibility.

A zero-footprint laboratory-information management suite, Sapphire is designed to manage an organization's critical laboratory information across worldwide operations, to optimize productivity, and more effectively share knowledge. The Sapphire BioBanking Solution ensures that standard procedures are used for all steps in the biorepository management process. Key processes supported include: informed consent, clinical data collection, sample collection, pathology review, biomolecule extractions, quality control, laboratory data collection, and biomolecule distribution.

A non-profit foundation, the IGC was established to expand upon the discoveries of the Human Genome Project and other systematic sequencing efforts by combining diagnostic technologies, genomic research, and bioinformatics, in the fight against cancer and other complex genetic diseases. The foundation has a number of functions including: standardization of the collection of properly consented tissues of interest, molecular characterization of these tissues, and standardization in the representation of these results. The IGC facilitates the transition of genomic discoveries to improve patient care and increase the speed in which new diagnostic, prognostic and predictive testing, and new drug and treatment regimens are developed.

The [U.S.] National Cancer Institute (NCI; Bethesda, MD, USA) and the [U.S.] National Human Genome Research Institute (NHGRI; Bethesda, MD) chose the IGC to lead the Human Cancer Biospecimen Core Resource (BCR) component of The Cancer Genome Atlas (TCGA) pilot project. The Sapphire BioBanking Solution will serve as a key informatics backbone supporting and maintaining the BCR.

"In order for the IGC to successfully implement the Human Cancer Biospecimen Core Resource we needed a biospecimen management solution that was functionally rich and capable of being implemented rapidly,” stated Troy Shelton, IGC project administrator for TCGA. "Among the software solutions we evaluated, LabVantage's Sapphire BioBanking Solution offered true out-of–the-box functionality and was by far the most well-established and premier solution used by peers in the industry.”


Related Links:
International Genomics Consortium
LabVantage Solutions
National Cancer Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.